Mepolizumab
- Generic Name
- Mepolizumab
- Brand Names
- Nucala
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 196078-29-2
- Unique Ingredient Identifier
- 90Z2UF0E52
- Background
Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm or more) is associated with a spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). The pathogenesis of eosinophilia is comp...
- Indication
Mepolizumab is an anti-IL-5 IgG1 kappa monoclonal antibody indicated as an add-on maintenance treatment in patients aged six years and older with severe eosinophilic asthma and as a treatment in adult patients for eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab is also indicated for the treatment of hypereosinophilic syndrome (HES) in patie...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Hypereosinophilic Syndrome (HES), Severe Eosinophilic Asthma
- Associated Therapies
- -
Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 674
- Registration Number
- NCT02105961
- Locations
- 🇬🇧
GSK Investigational Site, Stevenage, United Kingdom
Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
- Conditions
- Interventions
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 837
- Registration Number
- NCT02105948
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 347
- Registration Number
- NCT01691859
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
- Conditions
- Interventions
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 135
- Registration Number
- NCT01691508
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2012-02-07
- Target Recruit Count
- 48
- Registration Number
- NCT01520051
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis
- Conditions
- Interventions
- First Posted Date
- 2011-11-02
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 19
- Registration Number
- NCT01463644
- Locations
- 🇨🇦
Firestone Institute of Respiratory Health, St Joseph's Hospital, Hamilton, Ontario, Canada
Mepolizumab in Nasal Polyposis
- Conditions
- Interventions
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 109
- Registration Number
- NCT01362244
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome
- Conditions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2012-06-15
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 10
- Registration Number
- NCT00716651
- Locations
- 🇩🇪
University Hospital Schleswig Holstein, Rheumaklinik Bad Bramstetd, Bad Bramstedt, SH, Germany
Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 84
- Registration Number
- NCT00358449
- Locations
- 🇬🇧
GSK Investigational Site, Watford, United Kingdom
An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT00274703
- Locations
- 🇨🇭
GSK Investigational Site, Olten, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.